GHRP-2 vs CJC-1295

Side-by-side comparison of GHRP-2, CJC-1295 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute GHRP-2 Growth Hormone Releasing Peptide-2 Growth Hormone CJC-1295 CJC-1295 (Modified GRF 1-29) Growth Hormone
Basics
Molecular type Growth Hormone Releasing Peptide (GHRP)GHRH Analogue
Amino acids 629
Molecular weight 817.9 Da3,368.9 Da
Half-life ~1–2 hours30 min (without DAC) / 7–8 days (with DAC)
Route(s) Subcutaneous, Intramuscular, IntranasalSubcutaneous, Intramuscular
Mechanism & Research
Primary mechanism GHRP-2 activates the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus. Hypothalamic activation leads to reduced somatostatin tone (the GH release inhibitor), while pituitary activation directly triggers GH se… CJC-1295 binds GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and increasing GH pulse amplitude. Unlike native GHRH (half-life <10 minutes), the modified amino acid substitutions in CJC-1295 resi…
Research status Research Compound Research Compound
Evidence summary GHRP-2 has been extensively studied in humans including as a diagnostic tool for GH deficiency assessment. Its well-characterised dose-response relationship makes it a reference compound in the GHRP class. Phase 1/2 trials with CJC-1295 with DAC confirmed dose-dependent IGF-1 elevation lasting up to 14 days after single injection. CJC-1295 without DAC's pulsatile profile is primarily studied in combination with GHRPs.
Protocol & Dosing
Typical dose 100–200 mcg per injection100–200 mcg (without DAC); 2mg every 2 weeks (with DAC)
Frequency 2–3x daily2–3x daily (without DAC); biweekly (with DAC)
Duration 8–12 weeks8–16 weeks
Timing Fasted state; 2+ hours post-mealWithout DAC: fasted, 2x daily ideally morning + bedtime. With DAC: any time, biweekly.
Safety
Common side effects
  • Cortisol elevation (dose-dependent)
  • Prolactin increase (transient)
  • Increased appetite
  • Water retention
  • Water retention
  • Mild headache
  • Flushing (post-injection)
  • Tingling
Contraindications
  • Active malignancy
  • Hypothyroidism
  • Pregnancy
  • Active malignancy
  • Uncontrolled hypothyroidism
  • Pregnancy
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides Ipamorelin, CJC-1295, GHRP-6, Hexarelin Ipamorelin, Sermorelin, GHRP-2, Tesamorelin
Full profile Read full GHRP-2 profile → Read full CJC-1295 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.